Competition and donut hole discount takes toll on Xarelto sales

Johnson & Johnson, which sells Xarelto in the U.S., saw first quarter sales for the anticoagulant decline 6% despite pricing and prescription increases.

By Jonathan Gardner • April 23, 2019

J&J drugs sales outperform despite generic hit

Kicking off first quarter earnings for the industry, J&J managed to post better-than-expected pharma results despite falling Zytiga sales in the U.S.

By Ned Pagliarulo • April 16, 2019

Explore the Trendline➔

Drug pricing

Drug pricing legislation has put pharmaceutical companies on the defensive and created a new precedent for the industry.

By BioPharma Dive staff

Its ambitions restrained, Amgen sets modest Evenity price

The bone-building osteoporosis drug will carry a list price of $21,900 for a full course of treatment, a discount to competitors from Eli Lilly and Radius.

By Jonathan Gardner • April 16, 2019

Pharmacy's 'middlemen' counter pharma's campaign to shift the price blame

Banning rebates will not be a silver bullet leading to cost control, executives from PBMs argued in front of the Senate Finance Committee. 

By Jonathan Gardner • April 9, 2019

Copay assistance snares 3 drug companies in Medicare kickback charges

Alexion, Jazz and Lundbeck will pay $123 million to settle charges they used patient assistance foundations to boost prescriptions.

By Jonathan Gardner • April 5, 2019

What to look for after Zolgensma's launch

An ICER report provides clues on how payers will hedge their reimbursement bets for a likely million-dollar neuromuscular-disease treatment.

By Jonathan Gardner • April 4, 2019

AARP report offers window into generic drugmaker pain

Retail prices for knock-off medicines fell 9.3% in 2017, the group found. While good for patients, continued declines have put generic drugmakers in a bind.

By Ned Pagliarulo • April 4, 2019

Louisiana selects Gilead for subscription-based hep C program

Gilead beat out AbbVie and Merck to be the provider of the first-of-its-kind payment model, which focuses on prisoners and Medicaid patients.

By Andrew Dunn • March 27, 2019

Lilly reveals Humalog pricing details amid larger scrutiny over insulin costs

The average list price on the widely used insulin rose more than 50% from 2014 to 2018, though Lilly noted the drug's average net price declined 8%.

By Jacob Bell • March 25, 2019

Soon to depart, Scott Gottlieb keeps focus on greater drug competition

Increasing competition remains the outgoing FDA commissioner's remedy for drug market failures, which persist despite heightened public scrutiny.

By Ned Pagliarulo • March 20, 2019

Gilead raises prices on top-selling HIV treatments

The biotech hiked prices on more than a dozen products, including six HIV medicines that each surpassed $1 billion in 2018 sales.

By Andrew Dunn • March 19, 2019

Pharma's day in Congress: 'A hearing not a show'

Drugmaker executives avoided major missteps, but senators were successful in wringing acknowledgement that the current system isn't working.

By Ned Pagliarulo , Andrew Dunn • Feb. 26, 2019

In front of Congress, pharma execs blame 'broken' system

Top officials from the industry's largest drugmakers are testifying on drug pricing today in a Senate hearing billed as a showdown on the contentious issue.

By Ned Pagliarulo • Feb. 26, 2019

How lawmakers could pressure top pharma execs in Senate hearing

Here's a guide to the political pressure points for each of the seven drug companies in front of the Senate Finance Committee today.

By Ned Pagliarulo • Feb. 25, 2019

Insulin drugmakers again come under Senate scrutiny

Eli Lilly, Novo Nordisk and Sanofi now face pressure on their pricing practices from several key Congressional committees, including Senate Finance.

By Ned Pagliarulo • Feb. 22, 2019

Sanofi handed payers nearly $12B in drug rebates last year

That's why, despite increasing the U.S. list price on 35 of its 76 prescription drugs, the French pharma reported an average net price decline of 8% in 2018.

By Ned Pagliarulo • Feb. 21, 2019

Mylan launches Advair generic at 70% discount

While a long time coming, Mylan's copycat version now looks set to take a bite out of GSK's respiratory drug sales.

By Suzanne Elvidge • Feb. 13, 2019

Regeneron, Sanofi cut PCSK9 list price, matching earlier move by rival Amgen

The drugmakers will make Praluent available for 60% less than the cholesterol drug's original price, a decision reflective of persistent commercial hurdles.

By Ned Pagliarulo • Feb. 11, 2019

Vertex fears its triplet will also face UK reimbursement battle

U.K. regulators have already been in contentious battles with the biotech over its two-drug regimens for cystic fibrosis.

By Jacob Bell • Feb. 6, 2019

Pharma CEOs to testify in Senate drug pricing hearing

The heads of AbbVie and AstraZeneca, as well as J&J's pharma chief, all now plan to appear, joining their peers at what figures to be a high-profile event. 

By Ned Pagliarulo • Updated Feb. 11, 2019

Key Senate committee pressures 7 big pharmas to testify

Pfizer, J&J and AbbVie are among the major drugmakers invited by Senate Finance to discuss drug pricing at a hearing set for Feb. 26.

By Suzanne Elvidge • Updated Feb. 5, 2019

In hiking prices, drugmakers show some signs of tempering increases

Analysts at Raymond James found pharma price increases last month to be somewhat smaller than in January 2018 — evidence, perhaps, of some newfound restraint.

By Andrew Dunn • Feb. 4, 2019

Trump administration proposal takes aim at drug rebates

Billed by government officials as a sweeping reform, the plan aims to do away with price reductions paid by drugmakers to PBMs and insurers in Medicare.

By Ned Pagliarulo • Jan. 31, 2019

Pfizer, Novartis, Amgen add to 2019 drug price hikes

Prices were increased on major products including Novartis' Cosentyx, Pfizer's Xeljanz and Amgen's Enbrel.

By Andrew Dunn • Jan. 25, 2019

Senate Dems again targeting tax deductions for DTC drug ads

While the proposal has been put forward before, the Trump administration's plan to require drugmakers put prices in ads could give fresh momentum for such ideas.

By Jacob Bell • Jan. 23, 2019